For most pharmaceutical companies drug discovery is the starting point for innovation, market-leadership and profits. However, with the increasing number of chemical compounds being identified, drug discovery processes are becoming slower, more expensive and extremely slow causing new drug releases to almost come to a stand still.
Present day drug discovery frequently involves screening hundreds of thousands of compounds for biological activity against a 'target' molecule. These compounds or New Chemical Entities (NCEs) are thought to have properties useful for drug development but information on their properties, safety, toxicity, pharmacokinetics and metabolism in humans need, chemical makeup, stability and solubility need to be assessed first before the compound can be moved into the drug development pipeline for further testing, clinical trials and ultimately for NDA submission (New Drug Approval) to concerned regulatory bodies for marketing approval.
As patents on many older drugs are nearing expiry, pharmaceutical companies need to shift focus immediately to new drug discoveries. Large pharmaceutical manufacturers need to 'fuel their drug development pipelines' before their patents expire.
There is however, another angle to the slowing down of new drug discoveries. Many compounds are showing potential to be developed as drugs. With this increase in the numbers and complexity of 'compound libraries', new drug development processes are slowing down and becoming more time-consuming and expensive.
Current drug discovery technologies have to meet two challenges.
Some key drug development technology requirements are:
Software vendors are rising to the challenges from the pharmaceutical industry. Leading software vendors are developing sophisticated data management tools and research systems that do all this and much more. Highly automated detection and processing instruments are now available that can screen large numbers of compounds in a short period of time with little intervention from users. Software for drug discovery focuses on better tools of analysis and faster methods to handle growing volumes of research data.
Outsource2india provides leading pharmaceutical companies with cutting-edge tools that enhance their workflows and help towards better integration and analysis of R& D data. Our custom applications allow companies to streamline their drug discovery processes, innovate and stay ahead of competition.
Read more about outsourcing content management systems to O2I.